The dual mTORC1/2 inhibitor sapanisertib is being examined in the advanced setting in NSCLC (NCT02417701 and NCT04250545) based on preclinical evidence showing that NFE2L2 mutations induce mTOR pathway dependency. The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.